Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371"

Approved for use through 3/31/2007. OMB 0651-0021

U. S. PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
U.S. DEPARTMENT OF COMMERCE		BY0042P	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
		10/593540	
INTERNATIONAL APPLICATION NO.		PRIORITY DATE CLAIMED	
PCT/JP2005/005991	23 March 2005	23 March 2004	
TITLE OF INVENTION SUBSTITUTED QUINAZOLINE OF PYRIDOPYRIMIDINE DERIVATIVES			
APPLICANT(S) FOR DO/EO/US			
Morihiro Mitsuya, Makoto Bamba, Yasuhiro Sasaki, Teruyuki Nishimura, Junichi Eiki, and Keisuke Arakawa			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.			
4. The US has been elected (PCT Article 31).			
5. A copy of the International Application as filed [35 U.S.C. 371(c)(2)]			
a is attached hereto (required only if not communicated by the International Bureau).			
b. 🔀 has been communicated by the International Bureau.			
c. is not required, as the application was filed in the United States Receiving Office (RO/US).			
6. An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)].			
 a. X is attached hereto b. has been previously submitted under 35 U.S.C. 154(d)(4). 			
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)].			
a. are attached hereto (required only if not communicated by the International Bureau).			
b. have been communicated by the International Bureau.			
c. have not been made; however, the time limit for making such amendments has NOT expired.			
d. have not been made and will not be made.			
8. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].			
9. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].			
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT			
Article 36 [35 U.S.C. 371(c)(5)]. Items 11 to 20 below concern other document(s) or information included:			
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13. A preliminary amendment.			
14. An Application Data Sheet under 37 CFR 1.76.			
15. A substitute specification.			
16. A power of attorney and/or change of address letter.			
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.			
18. A second copy of the published International Application under 35 U.S.C.154(d)(4).			
19. A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).			
20. Other items or information:			
	•		

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Described and Conference of the Conferen Approved for use through 3/31/2007. OMB 0651-0021 ATTORNEY'S DOCKET NUMBER INTERNATIONAL APPLICATION NO. U.S. APPLICATION NO. (If known, see 37 CFR 1.5) BY0042P PCT/JP2005/005991 **CALCULATIONS** PTO USE ONLY Basic national fee......\$300 \$300.00 Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)......**\$0** \$200.00 Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by Search fee [37 CFR 1.445(a)(2)] has been paid on the international application to the USPTO as an \$500.00 International Search Report prepared by an ISA other than the US and provided to the Office or \$1000.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of Number of each additional 50 or fraction Total Sheets Extra Sheets RATE thereof (round up to a whole number) 111 - 100 =11 /50 \$250.00 \$250.00 Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)] CLAIMS NUMBER FILED NUMBER EXTRA RATE Total Claims \mathbf{X} \$0.00 - 20 = 0 \$50.00 Independent Claims Х \$0.00 - 3 = \$200.00 MULTIPLE DEPENDENT CLAIM(S) (if applicable) \$360.00 _ \$1,250.00 TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)]. TOTAL NATIONAL FEE \$1,250.00 Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).\$40.00 per property. TOTAL FEES ENCLOSED \$1,250.00 Amount to be refunded: Amount to be charged: A check in the amount of \$ __ ____ to cover the above fees is enclosed. Please charge my Deposit Account No. $\underline{13-2755}$ in the amount of $\underline{\$1,250.00}$ to cover the above fees. A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: Customer No. 000210 MERCK & CO., INC. Patent Department, RY60-30

Richard C. Billups **NAME** 31,916 **REGISTRATION NUMBER** Computer generated form "TransLetter (DO-EO-US)" (PCT Folder), Merck & Co., Inc., 7/27/2006

PHONE #:

P.O. Box 2000

126 East Lincoln Avenue Rahway, New Jersey 07065-0970

(732) 594-4683

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a submission Under 35 U.S.C. 371" Approved for use through 3/31/2007. OMB 0651-0021

IAP9/Rec'd PCT/PTO 19 SEP 2006

Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney Docket No.:	BY0042P	
International Appln No.:	PCT/JP2005/005991	
International Filing Date:	23 March 2005	
Priority Date:	23 March 2004	
Title:	SUBSTITUTED QUINAZOLINE OF PYRIDOPYRIMIDINE DERIVATIVES	

Inventors:

Morihiro Mitsuya, Makoto Bamba, Yasuhiro Sasaki, Teruyuki Nishimura, Junichi Eiki, and Keisuke Arakawa

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT

September 19, 2006

EXPRESS MAIL NO. EL 989585141 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY Christiae Cuffe DATE 9-19-06